Advances in Cancer Research: Current and Future Diagnostic . . . Another major challenge is the treatment and prognosis of CUP patients, with median survival rates reported between 2 and 12 months [6] Treatment primarily involves empirical chemotherapy (e g , taxane and platinum-based regimens), resulting in generally poor prognoses [7]
Cancer of Unknown Primary Site: A New Era of Practice . . . Management of CUP is undergoing rapid change including diagnoses of the presumed primaries, TNM staging, molecular characterization, improved outcomes, and an expanded role of precision site-specific therapies (SSTs) This review will highlight the emergent new era of clinical practice–changing management of patients
Cancer of unknown primary: ESMO Clinical Practice Guideline . . . CUP accounts for <5% of cancers but, because of its high mortality rate, its relative contribution to cancer deaths is higher 1 The incidence of CUP has been declining, probably due to improving success in localising primary tumours 2 The incidence increases with age and is higher in men compared with women Adenocarcinoma is the most common
Cancer of Unknown Primary (CUP) Treatment (PDQ®) Conceptually, CUP is a type of tumor that tends to metastasize early, unlike more common cases, in which the primary tumor is apparent, with or without metastasis The pattern of spread of CUP at diagnosis can provide clues to the likelihood of the primary site being above or below the diaphragm
Redefining cancer of unknown primary: Is precision medicine . . . CUP features significant oncological challenges, such as unravelling biological and transversal issues, and most importantly, improving patient’s outcomes In that regard, CUP patients’ outcomes regrettably showed minimal improvement for decades and CUP remains a cancer group of very poor prognosis The biology of CUP has two main hypotheses
Cancer of Unknown Primary Diagnostics: Insights for . . . Oncologists and researchers can improve CUP outcomes by adopting advanced Cancer of Unknown Primary diagnostics, such as IHC and molecular profiling View the OncologyTube video for a detailed overview of these strategies
Systematic review of the CUP trials characteristics and . . . The main topics were diagnostics (genomics) and treatment (empiric therapy) Ongoing trials focus on multiple tumour types and are primarily phase II single-arm trials Two clinical trial designs are suggested to improve the quality of CUP research